Venus Medtech (Hangzhou) Inc. (2500.HK)
- Previous Close
5.660 - Open
5.700 - Bid 5.620 x --
- Ask 5.680 x --
- Day's Range
5.500 - 5.940 - 52 Week Range
3.740 - 10.940 - Volume
6,416,000 - Avg. Volume
0 - Market Cap (intraday)
2.478B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-1.780 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.56
Venus Medtech (Hangzhou) Inc. engages in the research, development, clinical development, manufacturing, and commercialization of transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
www.venusmedtech.comRecent News: 2500.HK
Performance Overview: 2500.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2500.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2500.HK
Valuation Measures
Market Cap
2.48B
Enterprise Value
2.53B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.63
Price/Book (mrq)
0.79
Enterprise Value/Revenue
5.14
Enterprise Value/EBITDA
-3.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-146.71%
Return on Assets (ttm)
-7.69%
Return on Equity (ttm)
-22.84%
Revenue (ttm)
491.37M
Net Income Avi to Common (ttm)
-720.88M
Diluted EPS (ttm)
-1.780
Balance Sheet and Cash Flow
Total Cash (mrq)
781.64M
Total Debt/Equity (mrq)
28.47%
Levered Free Cash Flow (ttm)
--
Research Analysis: 2500.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 2500.HK
2500.HK does not have Company Insights